RBM-007 in Treatment naïve Exudative Age-related Macular Degeneration
Status:
Recruiting
Trial end date:
2022-07-30
Target enrollment:
Participant gender:
Summary
This study is a single-center, open label, 4-month study, designed to evaluate the safety and
treatment efficacy of RBM-007 in patients with intraretinal or subretinal edema due to
previously untreated neovascular AMD. Up to 5 subjects will be randomized to receive study
medication. Study treatment will be administered by intravitreal injections.